Hinge Health set to report earnings: Can growth momentum hold?

Hinge Health is set to release its third-quarter earnings on Monday, drawing investor attention to whether the digital physical therapy firm can maintain its rapid growth following a strong second quarter. Analysts forecast earnings of $0.21 per share, a significant drop from the $0.59 reported in the previous quarter. Despite this, Hinge Health has gained significant traction in the digital health sector, with shares increasing from $30.08 to $114.32 over the past year, nearly reaching its high of $117.55.

Currently, shares trade near consensus price targets of $114.31, leaving limited room for error as investors gauge the durability of the company's 50% revenue growth and gross margins exceeding 84%.

The market remains overwhelmingly bullish on Hinge Health, with 16 out of 17 analysts recommending a buy, and only one suggesting a hold. Several firms have recently raised their price targets, with Stifel boosting it to $130, BofA Securities to $130, and KeyBanc to $140. However, EPS estimates have dipped slightly by 2.94% over the past 60 days, while revenue estimates have remained stable.

App downloads and user engagement metrics will be closely monitored as indicators of business momentum. Stifel analyst David Grossman noted that September saw the strongest app downloads in 2026, continuing a rebound from August. Monthly active user declines have moderated, while engagement among active users has improved. Hinge Health's expansion beyond core musculoskeletal therapy is another key factor.

In early October, CEO Daniel Perez hinted at potential acquisitions, particularly in hardware, as the company aims to venture into adjacent healthcare markets. BofA Securities analyst Tomer Zilberman emphasized the importance of new product adoption and coverage of additional populations as growth drivers.

Sustaining margin sustainability is a major concern given Hinge Health's premium valuation. The company boasts impressive metrics, including approximately 50% topline growth, gross margins above 85%, and free cash flow margins exceeding 35%, according to BofA Securities. Investors will watch to see if the transition to a session-based pricing model and product expansion impact these margins.

Following an impressive second-quarter report of $0.59 per share on $212.8 million in revenue, which exceeded analyst forecasts, Hinge Health's shares rallied significantly. This strong performance underscored the company's potential to leverage employer demand for cost-effective musculoskeletal care solutions. The global digital MSK care market is valued at $6 billion, with increasing employer adoption of these platforms to cut healthcare costs and absenteeism.

The success of Hinge Health in maintaining its leadership position while expanding into new categories will be crucial in determining if current valuations, such as a forward P/E ratio of 47.4, are justified.